| abstract |
(R)-2-[4-(Trifluoromethanesulphonyloxy)phenyl]propionamide derivatives of_ formula (I), where the variables are as defined in the claims, and pharmaceutical compositions containing such compounds are useful in inhibiting. the chemotactic activation of neutrophils (PMN leukocytes) induced by the interaction of interieukin-8 (IL-8) with CXCRI and CXCR2 membrane receptors. The compounds are used for the prevention and treatment of pathologies deriving from said activation. Notably, these metabolites are devoid of cyclooxygenase inhibition. activity and are particularly useful in the treatment of neutrophil-dependent pathologies such as psoriasis, ulcerative colitis, melanoma, chronic obstructive pulmonary disease (COPD), bullous pemphigoid, rheumatoid arthritis, idiopathic fibrosis, glomerulonephritis and in the prevention and treatment of damages caused by ischemia and reperfusion. |